The association between the APE1 Asp148Glu polymorphism and prostate cancer susceptibility: a meta-analysis based on case-control studies

Mol Genet Genomics. 2015 Feb;290(1):281-8. doi: 10.1007/s00438-014-0916-3. Epub 2014 Sep 19.

Abstract

The apurinic/apyrimidinic endonuclease 1 (APE1) plays important roles in the repair of DNA damage and adducts. However, previous case-control studies on the association between the APE1 Asp148Glu polymorphism and prostate cancer susceptibility have shown contradictory results, this meta-analysis was performed to draw a more precise estimation of the relationship. A total of seven case-control studies including 1,294 cases and 1,762 controls were included for analysis. In overall, no significant associations were found in all genetic models (GG vs. TT: OR = 1.16, 95 % CI 0.89-1.52; TG vs. TT: OR = 1.04, 95 % CI 0.81-1.35; the dominant model GG + TG vs. TT: OR = 1.12, 95 % CI 0.96-1.30; the recessive model GG vs. TG + TT: OR = 0.90, 95 % CI 0.77-1.04); in the subgroup by source of control, we found a significant association for the dominant model in Hospital-based subgroup (OR = 1.34, 95 % CI 1.08-1.68), no significant associations were found in other models in the subgroups. This meta-analysis suggested that the APE1 Asp148Glu polymorphism was a risk factor for prostate cancer susceptibility in Hospital-based population.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • Confidence Intervals
  • DNA-(Apurinic or Apyrimidinic Site) Lyase / genetics*
  • Ethnicity / genetics
  • Genetic Association Studies*
  • Genetic Heterogeneity
  • Genetic Predisposition to Disease*
  • Humans
  • Male
  • Odds Ratio
  • Polymorphism, Single Nucleotide / genetics*
  • Prostatic Neoplasms / genetics*
  • Publication Bias

Substances

  • APEX1 protein, human
  • DNA-(Apurinic or Apyrimidinic Site) Lyase